Enfusion Statistics
Total Valuation
Enfusion has a market cap or net worth of $766.54 million. The enterprise value is $757.38 million.
| Market Cap | 766.54M |
| Enterprise Value | 757.38M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 91.91 million shares outstanding. The number of shares has decreased by -32.37% in one year.
| Shares Outstanding | 91.91M |
| Shares Change (YoY) | -32.37% |
| Shares Change (QoQ) | -29.83% |
| Owned by Insiders (%) | 7.61% |
| Owned by Institutions (%) | 95.97% |
| Float | 41.58M |
Valuation Ratios
The trailing PE ratio is 281.00 and the forward PE ratio is 32.52.
| PE Ratio | 281.00 |
| Forward PE | 32.52 |
| PS Ratio | 4.27 |
| Forward PS | 3.53 |
| PB Ratio | 13.35 |
| P/FCF Ratio | 47.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.27, with an EV/FCF ratio of 46.26.
| EV / Earnings | 298.06 |
| EV / Sales | 4.17 |
| EV / EBITDA | 34.27 |
| EV / EBIT | 289.30 |
| EV / FCF | 46.26 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.27.
| Current Ratio | 4.08 |
| Quick Ratio | 3.67 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 0.70 |
| Debt / FCF | 0.94 |
| Interest Coverage | -1.60 |
Financial Efficiency
Return on equity (ROE) is 4.80% and return on invested capital (ROIC) is 5.00%.
| Return on Equity (ROE) | 4.80% |
| Return on Assets (ROA) | 2.40% |
| Return on Capital (ROIC) | 5.00% |
| Revenue Per Employee | $164,806 |
| Profits Per Employee | $2,306 |
| Employee Count | 1,102 |
| Asset Turnover | 1.75 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $1.72 million in taxes.
| Income Tax | 1.72M |
| Effective Tax Rate | 40.34% |
Stock Price Statistics
The stock price has decreased by -24.28% in the last 52 weeks. The beta is 0.96, so Enfusion's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -24.28% |
| 50-Day Moving Average | 9.13 |
| 200-Day Moving Average | 9.09 |
| Relative Strength Index (RSI) | 36.41 |
| Average Volume (20 Days) | 368,889 |
Short Selling Information
The latest short interest is 1.58 million, so 1.72% of the outstanding shares have been sold short.
| Short Interest | 1.58M |
| Short Previous Month | 2.17M |
| Short % of Shares Out | 1.72% |
| Short % of Float | 3.80% |
| Short Ratio (days to cover) | 4.73 |
Income Statement
In the last 12 months, Enfusion had revenue of $181.62 million and earned $2.54 million in profits. Earnings per share was $0.03.
| Revenue | 181.62M |
| Gross Profit | 121.10M |
| Operating Income | 6.16M |
| Pretax Income | 4.26M |
| Net Income | 2.54M |
| EBITDA | 22.10M |
| EBIT | 2.62M |
| Earnings Per Share (EPS) | $0.03 |
Balance Sheet
The company has $32.89 million in cash and $15.46 million in debt, giving a net cash position of $17.43 million or $0.19 per share.
| Cash & Cash Equivalents | 32.89M |
| Total Debt | 15.46M |
| Net Cash | 17.43M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 58.05M |
| Book Value Per Share | 0.63 |
| Working Capital | 53.52M |
Cash Flow
In the last 12 months, operating cash flow was $26.24 million and capital expenditures -$9.87 million, giving a free cash flow of $16.37 million.
| Operating Cash Flow | 26.24M |
| Capital Expenditures | -9.87M |
| Free Cash Flow | 16.37M |
| FCF Per Share | $0.18 |
Margins
Gross margin is 66.68%, with operating and profit margins of 3.39% and 1.40%.
| Gross Margin | 66.68% |
| Operating Margin | 3.39% |
| Pretax Margin | 2.35% |
| Profit Margin | 1.40% |
| EBITDA Margin | 12.17% |
| EBIT Margin | 1.44% |
| FCF Margin | 9.02% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 32.37% |
| Shareholder Yield | 32.37% |
| Earnings Yield | 0.33% |
| FCF Yield | 2.11% |
Analyst Forecast
The average price target for Enfusion is $9.33, which is 12.01% higher than the current price. The consensus rating is "Sell".
| Price Target | $9.33 |
| Price Target Difference | 12.01% |
| Analyst Consensus | Sell |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Enfusion has an Altman Z-Score of 16.51 and a Piotroski F-Score of 5.
| Altman Z-Score | 16.51 |
| Piotroski F-Score | 5 |